Reimbursed Care Access in Niger

Currently classified as a strictly controlled substance under national drug scheduling laws and administered subject to Niger’s obligations as a party to the international drug control conventions, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Niger is listed among parties to the UN psychotropic substances framework that provides the baseline for national controls. #

There is no publicly available evidence of national registration or reimbursement for intranasal esketamine (brand products for resistant depression) in Niger; such specialty psychiatric products have not been recorded in Niger’s public procurement or national regulatory notices and would, if introduced, require explicit national marketing authorization and reimbursement decisions. Niger operates under international drug control obligations that restrict unlicensed distribution of psychotropic substances. #

Ketamine is used and procured as an injectable anesthetic in Niger’s health system and is listed on the WHO Model List of Essential Medicines as an injectable anaesthetic, which underpins its availability in many low- and middle-income country health services. #

Operational evidence of ketamine use in Niger’s hospitals includes documented emergency donations and supply deliveries to restore surgical and anesthetic capacity (example: Direct Relief donation of ketamine to the National Hospital in Niamey during an anesthesia shortage). This demonstrates routine clinical use of ketamine for anesthesia and emergency surgery in public hospitals rather than any licensed psychedelic psychiatric indication. #

Reimbursement and psychiatric use: there is no public evidence that ketamine is reimbursed or organized as a funded intervention for psychiatric indications (e.g., treatment-resistant depression) in Niger. Where ketamine exists in Niger it is procured and used primarily as an essential anesthetic in hospitals; off-label psychiatric infusion programs or esketamine-style nasal-product pathways and related reimbursement mechanisms have not been documented in Niger public health procurement records or national guidance. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Niger’s obligations under the UN psychotropic substances framework support national controls on DMT-containing preparations. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public documentation of permitted therapeutic programs or reimbursement for 5‑MeO‑DMT in Niger. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no publicly available evidence of authorized ibogaine treatment clinics or reimbursement in Niger. #

Preparations containing DMT (including ayahuasca) fall under the same international controls and are treated as strictly controlled in Niger; there is no recognized legal pathway for ritual/therapeutic ayahuasca use outside authorized research, and no reimbursement mechanisms. #

Mescaline and mescaline-containing cacti are subject to national control consistent with Niger’s treaty obligations; there is no authorized medical or reimbursed therapeutic use documented in national policy. #

Substituted phenethylamines (2C-series) are typically controlled under national psychotropic/drug laws in countries party to the UN psychotropic substances conventions; for Niger there is no evidence of authorized medical use or reimbursement—these substances are treated as illicit outside of approved research. #